ft 06 sep 94 technolog hand hand barrier biotechnolog pharmaceut gradual disappear technolog distinct biotechnolog pharmaceut becom nebul mani peopl industri differenti simpli larg compani mostli pharmaceut small compani mostli biotechnolog group drug discoveri method two field merg creat new multi facet approach pharmaceut start look biotechnolog differ industri part industri say jeremi levin presid new york base cadu pharmaceut biotechnolog compani realis lot learn pharmaceut compani term drug discoveri method result hotch potch tool rang structur base drug design crystallis x ray molecul come comput model robot screen use robot high speed random test pharmaceut quickli adopt consid biotechnolog method bristol myer squibb new york instanc say use comput base design tradit biotechnolog tool help come one best seller hypertens drug capoten biotechnolog compani becom adept tradit pharmaceut strength chemistri boundari two industri becom foggi chiron larg californian biotechnolog compani provid chemistri assist joint ventur syntex neighbour pharmaceut group chemistri syntex biolog say walter moo vice presid chiron technolog way usual work show weak divis day recent mani biotechnolog compani scorn pharmaceut old method random screen noth game chanc pharmaceut compani test hundr thousand compound laboratori achiev desir chemic reaction biotechnolog compani believ could find cure direct manner structur base design sometim call ration drug design allow look molecul detail answer mani believ studi particular molecular site bodi bind desir design molecul fit biotechnolog compani hope produc molecul like piec jigsaw puzzl creat exact match right place last year reveal weak comput base approach howev determin structur site difficult often depend abl turn floppi protein molecul crystal analysi structur comput softwar predict fit structur simpli may scientist often discov model weak soon begin test laboratori even new molecul fit site may lead cure especi complex diseas cancer arthriti aid idea target singl molecul could stop diseas say levin ill lot complic scientist come grip weak comput base design last year pharmaceut tradit screen method undergo renaiss sophist robot instanc mean compani screen compound far faster previous like gambl say prabha fernand vice presid bio molecular screen bristol myer squibb play better chanc get hit drug compani also start adopt screen method bundl dozen even thousand compound singl test tube get reaction immedi discard rapidli narrow field although screen method becom sophist increasingli view one tool drug discoveri process comput base design may perfect provid scientist key lead search right molecul see interplay screen ration drug design say marilyn hartig head extern scienc technolog bristol myer method get work work cycl get molecul want biotechnolog firm procept exampl use structur base design come lead clue right molecul look like follow extens screen defin shape size groov compar exist databas say jame jenson group chief scientist screen molecul think good chanc work biotechnolog method also use help build librari molecul screen lib rari databas natur synthet compound test effect treat certain diseas becom prioriti screen regain ground pharmaceut compani usual hold librari hundr thousand molecul biotechnolog compani start catch chiron instanc claim librari compar size mani larg pharmaceut group question remain whether new multi facet approach drug discoveri interim step industri wait structur base design method matur ration drug design get stronger one day abl stand alon predict peter johnson presid southern california agouron reli heavili comput base design last year boost screen capabl meanwhil increasingli complementari drug discoveri method use biotechnolog pharmaceut group probabl help stimul collabor two industri non technolog distinct biotechnolog pharmaceut group remain clear pharmaceut capit mani biotechnolog compani desper need biotechnolog group agil entrepreneuri attitud smaller compani need side cross increasingli technolog hemispher collabor becom even fruit